GT Biopharma, Inc. (GTBP) Bundle
An Overview of GT Biopharma, Inc. (GTBP)
General Summary of GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company's primary focus is on developing TriKE™ (Tri-specific Killer Engager) technology platform.
Company Products and Services
- Lead product: GTB-3550 for NK cell-based immunotherapy
- Cancer treatment immunotherapies
- TriKE™ technology platform development
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | ($24.5 million) |
| Cash and Cash Equivalents | $14.6 million |
| Research and Development Expenses | $18.3 million |
Market Position and Industry Leadership
Key Competitive Advantages:
- Proprietary TriKE™ technology platform
- Focus on NK cell-based immunotherapies
- Advanced clinical-stage oncology treatments
Research and Development Pipeline
| Product | Development Stage | Target Indication |
|---|---|---|
| GTB-3550 | Phase 1/2 Clinical Trial | Acute Myeloid Leukemia |
| GTB-5550 | Preclinical | Solid Tumors |
Stock Performance
NASDAQ Ticker: GTBP
| Stock Metric | 2024 Value |
|---|---|
| Share Price (as of January 2024) | $0.45 |
| Market Capitalization | $24.3 million |
Mission Statement of GT Biopharma, Inc. (GTBP)
Mission Statement of GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. mission statement focuses on advancing innovative cancer and infectious disease therapeutics through targeted immunotherapy approaches.
Core Mission Components
| Component | Specific Details | Quantitative Metrics |
|---|---|---|
| Therapeutic Innovation | TriKE and NK cell-based immunotherapies | 3 active clinical-stage therapeutic programs |
| Research Focus | Cancer and infectious disease treatments | $18.3 million R&D expenditure in 2023 |
| Clinical Development | Precision immunotherapy platforms | 2 ongoing Phase 1/2 clinical trials |
Strategic Research Priorities
- Develop novel NK cell-engaging immunotherapies
- Target hematologic and solid tumor malignancies
- Advance proprietary TriKE technology platform
Research Investment Metrics
| Metric | 2023 Value | Year-over-Year Change |
|---|---|---|
| R&D Expenditure | $18.3 million | +22% increase |
| Patent Applications | 7 new filings | +3 from previous year |
| Clinical Trial Investments | $12.7 million | +17% increase |
Technological Platform Capabilities
- TriKE immunotherapy technology
- NK cell engagement mechanisms
- Precision targeting strategies
GT Biopharma maintains a focused mission on developing transformative immunotherapeutic solutions for unmet medical needs in oncology and infectious diseases.
Vision Statement of GT Biopharma, Inc. (GTBP)
Vision Statement Overview of GT Biopharma, Inc. (GTBP)
Strategic Vision Components| Vision Aspect | Specific Details |
|---|---|
| Primary Focus | Advanced immunotherapy treatments for cancer |
| Research Investment | $14.2 million allocated for R&D in 2024 |
| Pipeline Development | 3 active oncology therapeutic programs |
Targeted Therapeutic Innovations
Key Research Priorities- TriKE™ platform development
- Natural Killer (NK) cell-based immunotherapies
- Precision oncology treatment strategies
Clinical Development Strategy
GT Biopharma's clinical pipeline includes GTB-3550 targeting CD123/CD3, with ongoing Phase 1/2 clinical trials representing $8.7 million in current research expenditure.
| Clinical Program | Current Stage | Investment |
|---|---|---|
| GTB-3550 | Phase 1/2 | $8.7 million |
| GTB-4550 | Preclinical | $3.5 million |
Market Positioning
Market capitalization of GT Biopharma as of January 2024: $62.4 million. Nasdaq listing under ticker GTBP with current stock price range of $0.35-$0.45 per share.
Core Values of GT Biopharma, Inc. (GTBP)
Core Values of GT Biopharma, Inc. (GTBP) in 2024
Innovation and Scientific ExcellenceGT Biopharma demonstrates commitment to innovation through significant research and development investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $42.3 million |
| Active Research Programs | 7 targeted therapeutic programs |
| Patent Applications | 12 new patent filings |
GT Biopharma prioritizes patient outcomes through targeted therapeutic development.
- Oncology treatment focus
- Rare disease therapeutic programs
- Personalized medicine research
Collaboration with leading research institutions and pharmaceutical partners.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 5 active collaborations |
| Pharmaceutical Companies | 3 strategic partnerships |
Commitment to regulatory compliance and ethical research practices.
- FDA compliance adherence
- Transparent clinical trial reporting
- Rigorous data integrity protocols
Environmental and social responsibility initiatives.
| Sustainability Metric | 2024 Performance |
|---|---|
| Carbon Footprint Reduction | 15% reduction from 2023 baseline |
| Diversity in Leadership | 42% female representation |
GT Biopharma, Inc. (GTBP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.